BioFactura, Inc.
- Biotech or pharma, therapeutic R&D
- CMO, CRO
BioFactura develops, manufactures and commercializes high-value biosimilars (generic biologics) using its patented StableFast™ Biomanufacturing Platform with faster, lower cost, superior-quality manufacturing processes.
Our near-term biosimilar assets in development include Stelara and Simponi. Stelara had approximately $15B in annual sales at the time of expiry in 2024. We have completed a successful Phase 1 clinical trial of our Stelara biosimilar in 2022. This asset has had successful tech transfer of methods and processes, resulting in an efficacious 500L scaled up perfusion BRX campaign.
This milestone clearly demonstrates the structural, physicochemical, and functional similarities we have demonstrated on an analytical basis, along with the clinical bioequivalence similarity data from our pivotal Phase 1 study,
We are seeking firms interested in in-licensing/acquiring our biosimilar assets for global or regional distribution.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}